Page 22 - Trials Network News Today

Analysis Demonstrates Effectiveness of LY-CoV555 Antibody in Preventing Symptomatic COVID-19 Analysis Demonstrates Effectiveness of LY-CoV555 Antibody in Preventing Symptomatic COVID-19 DURHAM, N.C., Jan. 25, 2021 — Researchers from the COVID-19 Prevention Network (CoVPN) announced that the monoclonal antibody (mAb), LY-CoV555 (bamlanivimab), evaluated in a Phase III trial significantly reduces the risk of contracting symptomatic COVID-19 as well as reduces the clinical course of...

For the first time, researchers say infusions of antibodies can prevent HIV infection Source: Corey L, et al. Abstract 1480. Presented at: HIV Research for Prevention; Jan. 27-28 and Feb. 3-4, 2021 (virtual meeting). Disclosures: Fauci reports no relevant financial disclosures. Healio could not confirm financial disclosures for Corey or Mgodi at the time of publishing. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please...

Share A large study in 11 countries tested whether infusions of monoclonal antibodies against HIV could protect people from infection. HIV Vaccine Trials Network Labmade antibodies can prevent HIV infection—but only if they match the virus Jan. 26, 2021 , 10:05 AM It has taken more than 4 years and $119 million for HIV researchers to test whether giving people infusions of antibodies made in a lab can protect them from the AIDS virus. Now, the unsatisfying answer is in: sometimes. Peo...

Cancer patients and the COVID-19 vaccines Clinicians, cancer patients and coronavirus researchers weigh in on vaccination safety, timing, allergy concerns and more January 14, 2021 • By Diane Mapes / Fred Hutch News Service Metastatic breast cancer patient and family doctor Dr. Carla Kakuta of Winters, California, receives her first COVID-19 shot, before heading off to cancer treatment. "I went straight from vaccination to the infusion center beca...

Through the Ride Health platform, a study coordinator can request rides on behalf of participants. (Ride Health) Access to private transportation, or lack thereof, has long been a barrier to participation in clinical trials. And COVID-19 isn’t making things easier, with public health guidelines discouraging the use of public transport and ride-hailing services setting up policies against passengers with COVID-19 symptoms. So, how are institutions running COVID-19 trials getting patien...

Cancer patients and the COVID-19 vaccines Clinicians, cancer patients and coronavirus researchers weigh in on vaccination safety, timing, allergy concerns and more January 14, 2021 • By Diane Mapes / Fred Hutch News Service Metastatic breast cancer patient and family doctor Dr. Carla Kakuta of Winters, California, receives her first COVID-19 shot, before heading off to cancer treatment. "I went straight from vaccination to the infusion center beca...

Have been provided with the technical expertise of ViiV Healthcare and a financial incentive from Unitaid via CHAI, to accelerate the development, registration, manufacture and supply of generic... | January 15, 2021

Press release content from Globe Newswire. The AP news staff was not involved in its creation. GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development GeoVax, Inc.January 11, 2021 GMT Company Focused on Single-dose Vaccine Against Multiple COVID Strains ATLANTA, GA, Jan. 11, 2021 (GLOBE NEWSWIRE) --   via NewMediaWire  --  GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that ...

WHAT: A collaborative approach to treating opioid use disorder that relies heavily on community pharmacists is feasible and may increase adherence and participant satisfaction, according to a pilot study published today in Addiction. The study was supported by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, through the NIDA Center for the Clinical Trials Network. Most people with opioid use disorder who would benefit from medication do not receive it. Bu...

January 6, 2021 Researchers at the  University of Maryland School of Medicine (UMSOM) will participate in a Phase 3 clinical trial of an investigational COVID-19 vaccine to protect against SARS-CoV-2, the coronavirus causing COVID-19 that continues to impact millions of people around the world. The clinical trial will test the safety and effectiveness of NVX-CoV2373, being developed by U.S. biotechnology company Novavax, Inc., based in Gaithersburg, MD. Clockwise from top left:...